A-86929 is a synthetic compound that acts as a selective dopamine receptorD1agonist. It was developed as a possible treatment for Parkinson's disease, as well as for other applications such as treatment of cocaine addiction, but while it had reasonable efficacy in humans it also caused dyskinesias and has not been continued. It has mainly been used as its diacetateesterprodrugadrogolide (ABT-431), which has better bioavailability.